Europe Bioreactors Market growth was valued at over USD 1.7 billion in 2019 and is expected to witness over 13.7% CAGR from 2020 to 2026.
Bioreactors are systems in which chemical/biological processes are carried out with the help of organisms or biochemically active substances. They are widely used in the areas of biopharmaceuticals, vaccines, and research and development of various novel entities.
Get more details on this report - Request Free Sample PDF
Increasing investment and funding by the government of various countries will favour Europe bioreactors market growth. The European Union is funding companies for the development of novel vaccines among others. For instance, it has offered USD 478 million for the WHO-led Covid-19 vaccine initiative. Such initiatives assist in bioreactors market expansion. Moreover, growing number of new biotechnology firms in the region will further boost adoption of bioreactors in the coming years.
Europe Market, By Product Type
Based on product type, bioreactors market is segmented as single-use bioreactors and reusable bioreactors. Single-use bioreactors segment is projected to progress at 16.7% CAGR during the analysis period. Single-use bioreactors are being extensively used in biomanufacturing facilities. They offer various advantages to the manufacturers such as flexibility in using the same floor space to manufacture different types of low-volume products, multiple product manufacture and reduction in cross-contamination. In addition, growing focus on research will accelerate the adoption of single-use bioreactors in the forthcoming years.
Europe Market, By Cell
Bioreactors market is segmented on the basis of cell as mammalian cells, bacterial cells, yeast cells and others. Bacterial cells segment held over 14% revenue share in 2019. Use of bacterial cells assist by improving oxygen and nutrients supply along with temperature control that helps in high density cultivation. Moreover, numerous large biopharma manufacturing firms are using microbial cells for production of various products, thereby augmenting the segment growth.
Europe Market, By Molecule
Based on molecule, bioreactors market is segmented as monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy and others. Recombinant proteins segment is set to witness more than 13.5% CAGR during the forecast timeframe. With advancing recombinant technology and growing incidence of rare diseases, the need for gene-based treatment is also increasing. Several companies are discovering new medicines based on recombinant proteins to cure such diseases. Moreover, rising importance of recombinant proteins in cellular and molecular biology will further impact the segment growth.
Europe Market, By End-user
On the basis of end-users, bioreactors market is segmented as R&D organizations, biopharmaceutical manufacturers, contract manufacturing organizations (CMOs). R&D organizations held USD more than 750 million revenue size in 2019. Growing number of research and development organizations along with favorable support from the government will help boost the segment size. In addition, the recent COVID-19 pandemic has created need for novel therapeutic and preventive medicine, thereby driving the demand for research. Such factors will create growth opportunities in the foreseeable future.
Europe Market, By Country
Germany bioreactors market held over 24% market share in 2019. Presence of prominent industry players in the nation will influence market growth. Presence of market players positively impact product availability and supply. In addition, continuously increasing innovations in the biopharmaceuticals sector and surging demand for monoclonal antibodies will further impel the demand for bioreactors in the Germany over the forecast years.
Competitive Market Share
Few of the established industry players involved in Europe bioreactors market include Sartorius Stedim Biotech, Pierre Guerin Sas, Danaher Corporation (Cytiva), and Eppendorf AG among others. Market players are undertaking various strategies such as collaborations, and product introduction to enhance their market foothold. For instance, in February 2020, Eppendorf launched SciVario twin, a bioreactor controller system for small bench-scale bioreactors. The launch of next generation bio controller enabled remote monitoring of cell culture processes, thereby enhancing its product portfolio.
During former times, bioreactors were utilized for making wine and beer for hundreds of years. Several players in the earlier period designed and developed bioreactors for food and beverage manufacturing; eventually entering biotechnology sector. Bioreactors are the most crucial equipment used in biotechnology. They yield products/substances in large amount in a controlled environment. With gradual development of new therapies such as cell and gene therapy, genetic engineering, recombinant technology among others, the demand for bioreactors grew substantially. Expanding pharma and biotechnology market subsequently augmented the market size and now, bioreactor systems have become indispensable in the industry. Market players have incorporated advancements in these systems to offer cost-effective solutions for small biologics manufacturers. Thus, with growing need for novel therapies and affordable equipment, the adoption of advanced bioreactors will increase in the forthcoming years.